Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

NEXT STORY
Digital PCR Market to Exhibit 17.2% CAGR and Reach USD 799.1 Million by 2026; Rise Remarkably on Account of Increasing Prevalence of Genetic Disorder Cases, reports Fortune Business Insights™
PREV STORY
Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Un essai de phase III montre que le nirsevimab protège les nourrissons en bonne santé contre les infections causées par le virus respiratoire syncytial

author_avatar
NASDAQ Market News

Results from Vericel’s Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented Today at ACC and Published in The Lancet

CAMBRIDGE, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer ...

author_avatar
NASDAQ Market News

Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma

author_avatar
NASDAQ Market News